Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the startup of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University. Follow Rob on Twitter @rob_cyran
- Tel: +1 646 223 6083
- E-mail: firstname.lastname@example.org
Regulators are giving consumers a boost by preventing broadband providers from offering favorable treatment to certain clients. But the telecoms giant expressed its discontent in Morse code and then in old typeset. Disagreeing is fine. Taunting your overseer, though, is a risky move.
Activist investor Jana and the $10 bln IT services firm’s bosses have incentives to sell. But past attempts to find a buyer for the company have foundered. Declining sales and vulnerable cash flow make it a tricky buyout candidate. Splitting it up may be a better first step.
The drugmaker’s pledge last year to focus on organic growth and debt reduction didn’t last long. Cost cuts and tax savings from buying Salix proved irresistible. What Valeant’s injecting isn’t clear. Salix’s numbers are fuzzy after it admitted pumping clients full of inventory.
- Easy money undermines Canada's property prudence
- Tesla's Apple math doesn't add up
- Yahoo's Alibaba spinoff attracts big discount
- Drugmakers unlikely candidates for next big short
- Scavengers pick at U.S. telecom price-war scraps
- Pfizer's generics injection lifts mood for breakup
- Prisoner's dilemma costs Gilead investors $15 bln